Allergan plc (NYSE:AGN) – Analysts at William Blair issued their Q2 2018 earnings per share (EPS) estimates for shares of Allergan in a research note issued to investors on Wednesday, according to Zacks Investment Research. William Blair analyst T. Lugo expects that the company will earn $3.17 per share for the quarter.
A number of other research analysts also recently issued reports on AGN. JPMorgan Chase & Co. set a $275.00 price objective on shares of Allergan and gave the company a “buy” rating in a research report on Sunday, October 22nd. Zacks Investment Research raised shares of Allergan from a “sell” rating to a “hold” rating in a research report on Monday, October 23rd. Royal Bank of Canada set a $250.00 price objective on shares of Allergan and gave the company a “buy” rating in a research report on Sunday, October 29th. They noted that the move was a valuation call. Cantor Fitzgerald set a $231.00 price objective on shares of Allergan and gave the company a “hold” rating in a research report on Wednesday, November 1st. Finally, Wells Fargo & Co reissued an “outperform” rating and set a $245.00 price objective (down from $258.00) on shares of Allergan in a research report on Thursday, November 2nd. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have given a buy rating to the stock. Allergan presently has an average rating of “Buy” and an average price target of $227.23.
Shares of Allergan (NYSE AGN) traded down $0.43 during midday trading on Friday, hitting $164.04. 2,647,430 shares of the company traded hands, compared to its average volume of 3,250,000. The company has a current ratio of 2.04, a quick ratio of 1.88 and a debt-to-equity ratio of 0.41. Allergan has a 12 month low of $156.00 and a 12 month high of $256.80. The stock has a market capitalization of $54,190.00, a P/E ratio of -13.68, a price-to-earnings-growth ratio of 1.16 and a beta of 1.19.
Allergan (NYSE:AGN) last issued its earnings results on Tuesday, February 6th. The company reported $4.86 EPS for the quarter, topping the consensus estimate of $4.74 by $0.12. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.28%. The company had revenue of $4.33 billion for the quarter, compared to the consensus estimate of $4.28 billion. During the same period in the previous year, the firm earned $3.90 earnings per share. The firm’s revenue for the quarter was up 12.0% on a year-over-year basis.
A number of institutional investors have recently made changes to their positions in the stock. Quadrant Capital Group LLC boosted its stake in Allergan by 1.4% in the 2nd quarter. Quadrant Capital Group LLC now owns 1,201 shares of the company’s stock worth $235,000 after purchasing an additional 16 shares in the last quarter. Auxier Asset Management boosted its stake in Allergan by 0.6% in the 2nd quarter. Auxier Asset Management now owns 8,010 shares of the company’s stock worth $1,947,000 after purchasing an additional 50 shares in the last quarter. Balentine LLC boosted its stake in Allergan by 5.6% in the 2nd quarter. Balentine LLC now owns 966 shares of the company’s stock worth $235,000 after purchasing an additional 51 shares in the last quarter. ELCO Management Co. LLC boosted its stake in Allergan by 2.9% in the 2nd quarter. ELCO Management Co. LLC now owns 2,132 shares of the company’s stock worth $518,000 after purchasing an additional 60 shares in the last quarter. Finally, Roberts Glore & Co. Inc. IL boosted its stake in Allergan by 1.1% in the 2nd quarter. Roberts Glore & Co. Inc. IL now owns 7,103 shares of the company’s stock worth $1,727,000 after purchasing an additional 75 shares in the last quarter. Institutional investors own 79.76% of the company’s stock.
In other Allergan news, Director Chris W. Bodine bought 3,030 shares of the company’s stock in a transaction dated Thursday, December 7th. The shares were purchased at an average price of $164.77 per share, for a total transaction of $499,253.10. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, insider William Meury sold 11,807 shares of the business’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $173.89, for a total transaction of $2,053,119.23. The disclosure for this sale can be found here. In the last 90 days, insiders have bought 17,630 shares of company stock worth $2,890,057. Company insiders own 0.36% of the company’s stock.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 28th. Stockholders of record on Wednesday, February 28th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.76%. The ex-dividend date of this dividend is Tuesday, February 27th. This is a boost from Allergan’s previous quarterly dividend of $0.70. Allergan’s payout ratio is -23.35%.
WARNING: “Analysts Offer Predictions for Allergan plc’s Q2 2018 Earnings (AGN)” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/18/william-blair-comments-on-allergan-plcs-q2-2018-earnings-agn.html.
Allergan Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Get a free copy of the Zacks research report on Allergan (AGN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.